| oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
| Terminated | 2b | 191 | Japan, US, Europe | sunitinib, Sutent, SU011248, mFOLFOX6, bevacizumab, Avastin | Pfizer | Colorectal Neoplasms | 07/11 | 07/11 | | |
NCT00016198: Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | 04/03 | 12/10 | | |
NCT00017082: Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Prologue Research International | Colorectal Cancer | 06/03 | 12/10 | | |
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
|
|
| Completed | 2 | 80 | US, Canada | lapatinib | GlaxoSmithKline | Colorectal Cancer | 10/03 | 10/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00399750: TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 373 | US | oxaliplatin, fluoropyrimidine, bevacizumab | Sanofi | Colorectal Cancer | | 06/05 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00215982: Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, XELODA™, Oxaliplatin, E LOXATIN™, Irinotecan, CAMPTOSAR™ | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Colorectal Cancer | 07/07 | 07/07 | | |
NCT00192075: A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 84 | US | Gemcitabine, Gemzar, avastin, 5FU/folinic acid, oxaliplatin | Eli Lilly and Company | Colorectal Cancer | | 11/07 | | |
| Completed | 2 | 215 | Canada, Europe | AZD2171, cediranib, RECENTIN™, 5-fluorouracil, 5-FU, Leucovorin, Oxaliplatin, Eloxatin®, Bevacizumab, Avastin® | AstraZeneca | Colorectal Cancer | 11/07 | 10/09 | | |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00345696 / 2005-006171-12: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
|
|
| Completed | 2 | 32 | Europe | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatine, Eloxatin | Unidad Integral de Investigación en Oncología S.L., Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/08 | 01/11 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT00419159 / 2006-003255-20: Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy |
|
|
| Completed | 2 | 199 | US | Everolimus (RAD001), Afinitor, Zortress, Certican | Novartis Pharmaceuticals | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00642603: A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 41 | US | capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan | Hoffmann-La Roche | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00118755: A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 435 | US | capecitabine, Oxaliplatin, bevacizumab | Hoffmann-La Roche | Colorectal Cancer | 04/09 | | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
XELOX-A-DVS, NCT00159432: Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | 63 | US | Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda | University of Southern California, Hoffmann-La Roche, Genentech, Inc. | Colorectal Cancer | 06/09 | 03/13 | | |
|
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
NCT00327119: Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
|
|
| Completed | 2 | 50 | Japan | ABX-EGF (panitumumab) | Amgen | Metastatic Colorectal Cancer | | | | |
| Completed | 2 | 44 | Europe | IMC-11F8 (necitumumab), Necitumumab, IMC-11F8, LY3012211, Portrazza®, Oxaliplatin, Folinic acid (FA), 5-FU | Eli Lilly and Company | Metastatic Colorectal Cancer | 01/10 | 10/10 | | |
NCT00601198: A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | Amifostine, Flurouracil (5-FU), Leucovorin calcium (LV), Oxaliplatin, Bevacizumab | University of Cincinnati, MedImmune LLC, AstraZeneca | Colorectal Cancer | 01/10 | 01/10 | | |
NCT01135498 / 2005-004662-16: A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 90 | Europe | bevacizumab [Avastin], eloxatin, capecitabine [Xeloda], erlotinib [Tarceva] | Hoffmann-La Roche | Colorectal Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 14 | Europe | Mangafodipir, Teslascan; ACT code V08CAE05, Placebo treatment (0.9% NaCl) | Egetis Therapeutics | Chemotherapy, Colon Cancer | 04/10 | 04/10 | | |
NCT01159171 / 2005-001012-41: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. |
|
|
| Completed | 2 | 50 | Europe | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 07/10 | 07/10 | | |
NCT00127036: Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) |
|
|
| Terminated | 2 | 65 | US | XELOX, Oxaliplatin and Capecitabine, XELIRI, Irinotecan and Capecitabine, Bevacizumab, Avastin® | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Adenocarcinoma, Colon Cancer | 12/10 | 12/10 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 199 | NA | Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI | Genentech, Inc. | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen |
|
|
| Completed | 2 | 171 | Japan, US, Canada, Europe, RoW | Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) | Pfizer | Colorectal Neoplasms | 03/11 | 04/12 | | |
|
|
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
| Completed | 2 | 48 | Canada, Europe | IMC-1121B (ramucirumab), ramucirumab, LY3009806, Oxaliplatin, Folinic acid, 5-FU | Eli Lilly and Company | Colorectal Carcinoma | 04/11 | 08/11 | | |
|
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
| Terminated | 2 | 9 | Europe | Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine | AIO-Studien-gGmbH, iOMEDICO AG | Colorectal Neoplasms | 11/11 | 03/12 | | |
NCT00642746: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) |
|
|
| Terminated | 2 | 16 | US | Erlotinib, Tarceva, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | OHSU Knight Cancer Institute, Genentech, Inc., OSI Pharmaceuticals | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT01077739 / 2009-012090-36: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin |
|
|
| Completed | 2 | 75 | Europe | fluorouracil (5FU), leucovorin, bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 01/12 | 01/12 | | |
NCT00177307: Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
|
|
| Completed | 2 | 40 | US | Bevacizumab, Capecitabine 2500 mg/m2/d in two divided doses, (May be 2000 or 3000 mg/m2/d after interim analysis) Days 1-8, every 2 weeks Until disease progression or unacceptable toxicity, Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,, or Grade 3 neuropathy or cumulative dose of 1200 mg/m2, Capecitabine, Oxaliplatin | University of Pittsburgh, Genentech, Inc. | Cancer | 02/12 | 02/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
NCT00721916: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 107 | Japan | SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin) | Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD | Colorectal Cancer | 03/12 | 05/12 | | |
| Completed | 2 | 54 | US, Europe, RoW | Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6) | Bayer | Colorectal Neoplasms | 03/12 | 06/14 | | |
|
NCT00677144: Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer |
|
|
| Completed | 2 | 88 | RoW | OS (oxalipaltin+S-1), Eloxatin, TS-1, XELOX (oxalipaltin+capecitabine), Xeloda | Hallym University Medical Center, Sanofi | Colorectal Neoplasm | 04/12 | 04/12 | | |
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer |
|
|
| Completed | 2 | 159 | US, Canada, Europe, RoW | ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil | AbbVie (prior sponsor, Abbott), Genentech, Inc. | Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/12 | 05/12 | | |
|
|
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
| Withdrawn | 2 | 0 | Canada | OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV), BEVACIZUMAB | Sanofi | Colorectal Neoplasms | 05/12 | 05/12 | | |
NCT01175291: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | MK-0646, oxaliplatin, leucovorin, 5-FU, Fluorouracil, bevacizumab, Placebo, 5-Fluorouracil | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 07/12 | 07/12 | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
| Completed | 2 | 47 | Europe | Cetuximab, Erbitux, Irinotecan, Camptosar, Oxaliplatin, Eloxatin, UFT, Tegafur, Uracil | The Christie NHS Foundation Trust, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 05/13 | 05/13 | | |
|
| Completed | 2 | 76 | US, Europe | Panitumumab, Vectibix, Ganitumab, AMG 479, Irinotecan | Amgen | Metastatic Colorectal Cancer | 07/13 | 07/13 | | |
NCT01478594 / 2011-003502-24: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy |
|
|
| Completed | 2 | 265 | US, Canada, Europe, RoW | Tivozanib, AV951, ASP4130, Bevacizumab, Avastin, mFOLFOX6 | AVEO Pharmaceuticals, Inc. | Colorectal Cancer | 09/13 | 01/15 | | |
|
|
|
|
|
|
|
|
| Completed | 2 | 80 | Europe | 5-FU, Irinotecan, Leucovorin, Oxaliplatin, bevacizumab [Avastin] | Hoffmann-La Roche | Colorectal Cancer | 10/13 | 10/13 | | |
|
SETICC, NCT01071655 / 2009-012562-31: Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 195 | Europe | BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX, BVZ+XELOX | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Hoffmann-La Roche | Colorectal Cancer | 11/13 | 11/13 | | |
NCT00959647: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study |
|
|
| Completed | 2 | 19 | US | Vismodegib, Erivedge, GDC-0449, RO5450815, FOLFOX, FOLFIRI, Bevacizumab, Avastin | Genentech, Inc. | Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer | 01/14 | 01/14 | | |
| Completed | 2 | 97 | Europe | 5-FU, bevacizumab [Avastin], irinotecan, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
|
|
NCT01399684 / 2011-001867-28: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 127 | US, Europe, RoW | 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo | Genentech, Inc. | Metastatic Colorectal Cancer | 02/14 | 02/14 | | |
NCT01226719: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only |
|
|
| Completed | 2 | 15 | US | Panitumumab, Combined Modality Treatment, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil | SCRI Development Innovations, LLC, Amgen | Colorectal Cancer | 03/14 | 03/14 | | |
|
NCT01378143: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy |
|
|
| Completed | 2 | 53 | Canada | OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI | Oncozyme Pharma Inc. | Colorectal Cancer | 03/14 | 07/14 | | |
APEC-Study, NCT00778830: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 289 | RoW | Cetuximab, Erbitux, FOLFIRI, FOLFOX | Merck KGaA, Darmstadt, Germany, Merck Pte. Ltd., Singapore | Metastatic Colorectal Cancer | 04/14 | 04/14 | | |
|
|
|
|
|
| Completed | 2 | 77 | Europe | 5-Fluorouracil (5-FU), Bevacizumab, Avastin, Levofolinic acid, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 05/14 | 05/16 | | |
NCT00165854 / 2004-002597-33: Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 46 | Europe | E7070 | Eisai Limited | Colorectal Cancer (CRC) | | | | |
NCT01322815: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI |
|
|
| Terminated | 2 | 11 | US | chemotherapy and GI-4000, 5-fluorouracil (5-FU), leucovorin. oxaliplatin, 5-fluorouracil (5-FU), leucovorin, irinotecan, avastin, GI-4000, Avastin | Georgetown University, GlobeImmune | Colon Cancer | 09/14 | 12/15 | | |
| Terminated | 2 | 266 | US, Europe, RoW | Simtuzumab, SIM; GS-6624, Placebo to match SIM, Leucovorin, Folinic acid, Irinotecan, Fluorouracil | Gilead Sciences | Colorectal Cancer | 10/14 | 02/15 | | |
| Completed | 2 | 80 | Europe | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen | Colorectal Cancer | 03/15 | 03/15 | | |
|
|
|
|
MAVERICC, NCT01374425 / 2011-004755-39: Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 376 | US, Canada, Europe | 5-Fluorouracil, Bevacizumab, Avastin, Irinotecan, Leucovorin, Oxaliplatin, Capecitabine | Genentech, Inc. | Colorectal Cancer | 05/15 | 07/15 | | |
|
|
|
NCT01882868: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan |
|
|
| Completed | 2 | 62 | Japan | Aflibercept, AVE0005, Levofolinate, Irinotecan, 5-FU | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/15 | 08/15 | | |
NCT02046538: Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Leucovorin, Wellcovorin, Oxaliplatin, Eloxatin, 5-FU, Adrucil, fluorouracil, Irinotecan, Camptosar | Weill Medical College of Cornell University, Sanofi | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 02/16 | 02/18 | | |
PREVIUM, NCT02175654 / 2014-000703-26: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab |
|
|
| Terminated | 2 | 15 | Europe | Regorafenib | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Bayer | Colorectal Neoplasms, Metastatic Disease | 02/16 | 02/16 | | |
| Completed | 2 | 186 | US, Europe, RoW | PledOx (2 µmol/kg), Calmangafodipir, PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl), Sodium chloride | Egetis Therapeutics, Pharma Consulting Group AB | Advanced Metastatic (Stage IV) Colorectal Cancer | 03/16 | 12/16 | | |
STEAM, NCT01765582: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 280 | US | 5-fluorouracil, bevacizumab, Avastin, capecitabine, Xeloda, irinotecan, folinic acid, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Neoplasms | 03/16 | 03/16 | | |
|
|
| Completed | 2 | 91 | Europe | Bevacizumab, Avastin, Oxaliplatin, Folinic Acid, 5-fluorouracil, Preoperative Radiotherapy, Surgery | Hoffmann-La Roche | Rectal Cancer | 03/16 | 03/16 | | |
|
NCT01889680: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | 5-FU, 5-fluorouracil, LV, leucovorin, ziv-aflibercept, mFOLFOX6, 5-FU plus leucovorin plus oxaliplatin | NSABP Foundation Inc, Sanofi | Colorectal Cancer, Metastatic Colorectal Cancer | 05/16 | 05/18 | | |
NCT02085005: Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669 | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/16 | 08/16 | | |
| Completed | 2 | 250 | Europe | Oxaliplatin, 5FU/LV, Bevacizumab, Bevacizumab, Oxaliplatin, I-LV, 5-FU, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan, Irinotecan | Martin-Luther-Universität Halle-Wittenberg, Roche Pharma AG | Metastatic Colorectal Cancer | 09/16 | 08/18 | | |
| Terminated | 2 | 44 | Europe | FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG | Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer | 09/16 | 09/16 | | |
|
PRIMIER, NCT02413853: Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | CBP/beta-catenin Antagonist PRI-724, PRI-724, Wnt signaling pathway inhibitor PRI-724, Bevacizumab, Avastin, rhuMab-VEGF, Leucovorin Calcium, CF, Oxaliplatin, Fluorouracil, Laboratory Biomarker Analysis | University of Southern California, National Cancer Institute (NCI), Prism Pharma Co., Ltd. | Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer | 11/17 | 11/18 | | |
NCT02079220: A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Arm A, Xeloda, ELOXATIN, ZALTRAP, Arm B | James J Lee, Sanofi | Metastatic Colorectal Cancer | 03/18 | 03/18 | | |
POLAF, NCT02970916 / 2016-001508-45: Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms |
|
|
| Completed | 2 | 100 | Europe | FOLFIRI+aflibercept | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi | Metastatic Colorectal Cancer | 05/18 | 12/18 | | |
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
NCT00625651: Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer |
|
|
| Completed | 1b/2 | 202 | US | Placebo, AMG 655, Modified FOLFOX6, mFOLFOX6, Bevacizumab | Amgen | Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer | 08/10 | 09/11 | | |
CORGI, NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer |
|
|
| Completed | 1/2 | 106 | Europe | oxaliplatin, capecitabine, radiotherapy | Lund University Hospital, Roche Pharma AG, Sanofi-Synthelabo | Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer | 07/07 | 07/09 | | |
NCT00226941: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
|
|
| Terminated | 1/2 | 23 | US | Cetuximab, Erbitux, C225, IMC-C225, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT, Diphenhydramine hydrochloride (HCl), Benadryl, Unisom, Sominex | George Albert Fisher, Bristol-Myers Squibb | Rectal Cancer, Colo-rectal Cancer | 03/08 | 02/09 | | |
NCT00345761: Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer |
|
|
| Completed | 1/2 | 64 | Japan | Bevacizumab, Oxaliplatin, Capecitabine | Chugai Pharmaceutical, Yakult Honsha Co., LTD | Colorectal Cancer | 10/08 | 07/10 | | |
NCT00536809: Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 12 | US | lapatinib, oxaliplatin, capecitabine | GlaxoSmithKline | Neoplasms, Colorectal | 10/08 | 10/08 | | |
NCT00494221: A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX |
|
|
| Completed | 1/2 | 172 | Japan | AZD2171, cediranib, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Eloxatin®, 5-FU, Leucovorin, Placebo Cediranib | AstraZeneca | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
| Completed | 1/2 | 51 | Europe | Oxaliplatin, Capecitabine, Bevacizumab, Imatinib, Xeloda, Avastin, Imatinib, Eloxatin | University of Cologne, Roche Pharma AG, Novartis, Sanofi | Stage IV Colorectal Cancer | 08/10 | 12/12 | | |
|
IMA910-101, NCT00785122 / 2007-005666-12: IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy |
|
|
| Completed | 1/2 | 92 | Europe, RoW | Endoxana, Leukine, IMA910, Endoxana (Cyclophosphamide), Aldara (Imiquimod), IMA910, GM-CSF, Endoxana, Leukine, IMA910, Aldara | Immatics Biotechnologies GmbH | Colorectal Carcinoma | 01/11 | 05/13 | | |
NCT00809796: A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment |
|
|
| Completed | 1/2 | 15 | Canada | pentamidine | Oncozyme Pharma Inc. | Colorectal Cancer | 05/11 | 06/11 | | |
NCT00819754: A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 1/2 | 23 | Canada | IXO regimen + bevacizumab, irinotecan - Camptosar, capecitabine - Xeloda, Oxaliplatin - Eloxatin, bevacizumab - Avastin | Ottawa Hospital Research Institute, Hoffmann-La Roche, Pfizer, Sanofi, Ottawa Regional Cancer Foundation | Metastatic Colorectal Cancer | 02/12 | 05/12 | | |
|
NCT01955629 / 2013-000858-22: Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient |
|
|
| Terminated | 1/2 | 4 | Europe | Aflibercept AVE0005, Zaltrap, Oxaliplatin, Eloxatin, SR96669, Capecitabine | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 03/15 | 03/15 | | |
NCT01047293: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma |
|
|
| Completed | 1/2 | 47 | US | RAD001, everlomius, FOLFOX, oxaliplatin + 5 FU + leucovorin, Bevacizumab, Avastin | University of Utah, Novartis | Colorectal Cancer | 08/15 | 08/15 | | |
|
